Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 10/20 | 0.41 |
| ▸ | F7 | P08709 | 9/20 | 0.41 |
| ▸ | F2 | P00734 | 8/20 | 0.41 |
| ▸ | F10 | P00742 | 7/20 | 0.41 |
| ▸ | PLG | P00747 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295760 | 0.93 | F3 (0.43) | F3F7F2F10PLG | |
| SCHEMBL6300656 | 0.87 | F3 (0.42) | F3F7F2F10PLG | |
| SCHEMBL6294688 | 0.84 | PYGL (0.43) | F3F7F2F10PLG | |
| SCHEMBL8498736 | 0.79 | F3 (0.59) | F3F7F2F10PLG | |
| SCHEMBL6300732 | 0.77 | F3 (0.46) | F3F7F2F10PLG | |
| Trifluoroacetic Acid SCHEMBL6300715 | 0.76 | F3 (0.55) | F3F7F2F10PLG | |
| SCHEMBL7663258 | 0.75 | F3 (0.45) | F3F7F2F10PLG | |
| SCHEMBL8506173 | 0.75 | F7 (0.65) | F3F7F2F10PLG | |
| SCHEMBL6300730 | 0.69 | SCN9A (0.40) | F3F7F2F10PLG | |
| SCHEMBL7663122 | 0.69 | F3 (0.50) | F3F7F2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916837-B2 | Amidino derivatives and anticoagulants and thrombosis therapeutic agents containing them | EISAI CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20030181766-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1312602-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | Eisai Co., Ltd. (JP) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181766-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | F2, SERPINC1, F12 | F3 56/4885F7 22/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.